Breast cancer and depression

ONCOLOGY

Volumn 18, Issue 8, 2004, Pages 1021-1034

  Somerset, Wendy ^a   Stout, Steven C ^a   Miller, Andrew H ^a   Musselman, Dominique ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; ANTINEOPLASTIC AGENT;

BREAST TUMOR; CLINICAL TRIAL; COMORBIDITY; DEPRESSION; FEMALE; HUMAN; HYPOPHYSIS ADRENAL SYSTEM; HYPOTHALAMUS HYPOPHYSIS SYSTEM; PATHOPHYSIOLOGY; PHYSIOLOGY; PROGNOSIS; PSYCHOLOGICAL ASPECT; QUALITY OF LIFE; REVIEW; SURVIVAL;

ANTIDEPRESSIVE AGENTS; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CLINICAL TRIALS; COMORBIDITY; DEPRESSIVE DISORDER; FEMALE; HUMANS; HYPOTHALAMO-HYPOPHYSEAL SYSTEM; PITUITARY-ADRENAL SYSTEM; PROGNOSIS; QUALITY OF LIFE; SURVIVAL;

EID: 5144231447     PISSN: 08909091     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (125)

1. Ayres A, Hoon PW, Franzoni JB, et al: Influence of mood and adjustment to cancer on compliance with chemotherapy among breast cancer patients. J Psychsom Res 38:393-402, 1994.
2. Colleoni M, Mandala M, Peruzzotti G, et al: Depression and degree of acceptance of adjuvant cytotoxic drugs. Lancet 356:1326-1327, 2000.
3. Day R: National Surgical Adjuvant Breast and Bowel Project study. Quality of life and tamoxifen in breast cancer prevention trial: A summary of findings from the NSABP P-1 study. Ann N Y Acad Sci 949:143-150, 2001.
4. Watson M, Haviland JS, Greer S, et al: Influence of psychological response on survival in breast cancer: A population-based cohort study. Lancet 354:1331-1336, 1999.
5. Hjerl K, Andersen EW, Keiding N, et al: Depression as a prognostic factor for breast cancer mortality. Psychosomatics 44:24-30, 2003.
6. Fras I, Litin EM, Pearson JS: Comparison of psychiatric symptoms in carcinoma of the pancreas with those in some other intrabdominal neoplasma. Am J Psychiatry 123:1553-1562, 1967.
7. Joffe RT, Rubinow DR, Denicoff KD, et al: Depression and carcinoma of the pancreas. Gen Hosp Psychiatry 8:241-245, 1986.
8. Morton RP, Davies ADM, Baker J, et al: Quality of life in treated head and neck cancer patients: A preliminary report. Clin Otolaryngol 9:131-185, 1984.
9. Baile WF, Bilbertini M, Scott L, et al: Depression and tumor stage in cancer of the head and neck. Psychooncology 1:15-24, 1992.
10. D'Antonio LL, Long SA, Zimmerman GJ, et al: Relationship between quality of life and depression in patients with head and neck cancer. Laryngoscope 108:806-811, 1998.
11. Plumb MM, Holland J: Comparative studies of psychological function in patients with advanced cancer. I. Self-reported depressive symptoms. Psychosom Med 39:264-276, 1977.
12. Hosaka T, Awazu H, Aoki T, et al: Screening for adjustment disorders and major depression in otolaryngology patients using the Hospital Anxiety and Depression Scale. Int J Psychiatry Clin Pract 3:43-48, 1999.
13. Koenig R, Levin SM, Brennan MT: The emotional status of cancer patients as measured by a psychological test. J Chronic Dis 20:923-930, 1967.
14. Maguire GP, Lee EG, Bevington DJ, et al: Psychiatric problems in the first year after mastectomy. Br Med J 1:963-965, 1978.
15. Silverfarb PM, Maurer LH, Crouthamel CS: Psychological aspects of neoplastic disease, I: Functional status of breast cancer patients during different treatment regimens. Am J Psychiatry 137:450-455, 1980.
16. Farber JM, Weinerman BH, Kuypers JA: Psychological distress in oncology outpatients. J Psychosocial Oncol 2:109-118, 1984.
17. Grandi S, Fava GA, Cunsolo A, et al: Major depression associated with mastectomy. Med Sci Res 15:283-284, 1987.
18. Fallowfield LJ, Hall A, Maguire GP, et al: Psychological outcomes of different treatment policies in women with early breast cancer outside of a clinical trial. Br Med J 301:575-580, 1990.
19. Hopwood P, Howell A, Maguire P: Screening for psychiatric morbidity in patients with advanced breast cancer: Validation of two self-report questionnaires. Br J Cancer 64:353-356, 1991.
20. Hopwood P, Howell A, Maguire P: Psychiatric morbidity in patients with advanced cancer of the breast: Prevalence measured by two self-rating questionnaires. Br J Cancer 64:349-352, 1991.
21. Goldberg JA, Scott RN, Davidson PM: Psychological morbidity in the first year after breast surgery. Eur J Surg Oncol 18:327-331, 1992.
22. Pinder KL, Ramirez M, Black E, et al: Psychiatric disorder in patients with advanced breast cancer: Prevalence and associated features. Eur J Cancer 29(supplA):524-527, 1993.
23. Rowland JH: Anxiety and the blues after breast cancer: How common are they? CNS Spectrums 4:40-54, 1999.
24. Wenzel LB, Fairclough DL, Brady MJ, et al: Age-related differences in the quality of life of breast carcinoma patients after treatment. Cancer 86:1768-1774, 1999.
25. Evans DL, McCartney CF, Nemeroff CB, et al: Depression in women treated for gynecological cancer: Clinical and neuroendocrine assessment. Am J Psychiatry 143:447-452, 1986.
26. Golden RN, McCartney CF, Haggerty JJ, et al: The detection of depression by patient self-report in women with gynecologic cancer, Int J Psychiatry Med 21:11-27, 1991.
27. Cerfolio N: Psychiatric liaison to gynecological oncology. Psychooncology 4:143-147, 1995.
28. Cull A, Cowie VJ, Farquharson DI, et al: Early stage cervical cancer: Psychosocial and sexual outcomes of treatment. Br J Cancer 68:1216-1220, 1993.
29. Devlen J, Maguire P, Phillips P, et al: Psychological problems associated with diagnosis and treatment of lymphomas, I: Retrospective study. Br Med J 295:953-954, 1987.
30. Colon EA, Callies AL, Popkin MK, et al: Depressed mood and other variables related to bone marrow transplantation survival in acute leukemia. Psychosomatics 32:420-425, 1991.
31. Beck AT, Ward CH, Mendelson M, et al: An inventory for measuring depression. Arch Gen Psychiatry 4:561-571, 1961.
32. Radloff LS: The CES-D scale: A self-report depression scale for research in the general population. J Applied Psychological Measurement 1:385-401, 1977.
33. Carroll BJ, Feinberg M, Smouse PE, et al: The Carroll rating scale for depression: I. Development, reliability and validation. Br J Psychiatry 138:194-200, 1981.
34. Johnstone A, Goldberg D: Psychiatric screening in general practice. A controlled trial. Lancet 1:605-608, 1976.
35. Zigmond AS, Snaith RP: The hospital anxiety and depression scale. Acta Psychiatr Scand 67:361-370, 1983.
36. Hamilton M: A rating scale for depression. J Neurol Neurosurg Psychiatry 23:56-62, 1960.
37. Derogatis LR, Lipman RS, Rickels K, et al: The Hopkins Symptom Checklist (HSCL): A self-report symptom inventory. Behav Sci 19:1-15, 1974.
38. Hathaway SR, McKinley JC: Minnesota Multiphasic Personality Inventory Manual, revised ed. New York, Psychological Corp, 1951.
39. Endicott J, Spitzer RL: A diagnostic interview: The Schedule for Affective Disorders and Schizophrenia. Arch Gen Psychiatry 35:837-844, 1978.
40. Spitzer RL, Williams JBW, Gibbon M, et al: Structured Clinical Interview for DSM-III-R (SCID). New York, Biometrics Research Department, New York State Psychiatric Institute, 1987.
41. Stewart MA, Drake WGW: Depression among medically ill patients. Dis Nervous System 115:1365-1369, 1968.
42. Kessler RC, McGonagle KA, Zhao S, et al: Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Arch Gen Psychiatry 51:8-19, 1994.
43. Ashby MJ, Kissane DW, Beadle GF, et al: Psychosocial support, treatment of metastatic disease and palliative care. Med J Aust 164:43-49, 1996.
44. Bower JE, Ganz PA, Aziz N, et al: Fatigue and proinflammatory cytokine activity in breast cancer survivors. Psychosom Med 64:604-611, 2002.
45. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, 4th ed. Washington, DC, American Psychiatric Association, 1994.
46. Broadhead WE, Blazer DG, George LK, et al: Depression, disability days, and days lost from work in a prospective epidemiologic survey. JAMA 264:2524-2528, 1990.
47. Dube S, Anda R, Felitti V, et al: Childhood abuse, household dysfunction, and the risk of attempted suicide throughout the lifespan: Findings from the adverse childhood experiences study. JAMA 286:3089-3096, 2001.
48. McCauley J, Kern DE, Kolodner K, et al: Clinical characteristics of women with a history of childhood abuse: Unhealed wounds. JAMA 277:1362-1368, 1997.
49. Rodrigue JR, Park TL: General and illness-specific adjustment to cancer: Relationship to marital status and marital quality. J Psychosom Res 40:29-36, 1996.
50. Zimmerman L, Story KT, Gaston-Johansson F, et al: Psychological variables and cancer pain. Cancer Nurs 19:44-53, 1996.
51. Weinstein SP: Cancer pain management. TEN 4:48-55, 2002.
52. Spiegel D, Sands S, Koopman C: Pain and depression in patients with cancer. Cancer 74:2570-2578, 1994.
53. Henriksson MM, Isometsa ET, Hietanen PS, et al: Mental disorders in cancer suicides. J Affect Dis 36:11-20, 1995.
54. Kugaya A, Akechi T, Okuyama T, et al: Prevalence, predictive factors, and screening for psychologic distress in patients with newly diagnosed head and neck cancer. Cancer 88:2817-2823, 2000.
55. Rouchell AM, Pounds R, Tierney JG: Depression, in Rundell JR, Wise MG (eds): Textbook of Consultation-Liason Psychiatry. Washington, DC, American Psychiatric Press, 1996.
56. Bower JE, Ganz PA, Desmond KA, et al: Fatigue in breast cancer survivors: occurrence, correlates, and impact on quality of life. J Clin Oncol 18:743-753, 2000.
57. Bukberg J, Penman D, Holland JC: Depression in hospitalized cancer patients. Psychosom Med 46:199-212, 1984.
58. Evans DL, McCartney CF, Haggerty JJ: Treatment of depression in cancer patients is associated with better life adaptation: A pilot study. Psychosom Med 50:72-76, 1988.
59. Rubinow DR, Schmidt PJ, Roca CA: Estrogen-serotonin interactions: Implications for affective regulation. Biol Psychiatry 44:839-850, 1998.
60. Owens MJ, Stout SC, Mulchahey JJ, et al: Molecular and neurobiological mechanisms in the treatment of psychiatric disorders, in Tasman A, Kay J, Lieberman JA (eds): Textbook of Psychiatry. Philadelphia, WB Saunders, 1996.
61. Lee SJ, McEwen BS: Neurotrophic and neuroprotective actions of estrogens and their therapeutic implications. Ann Rev Pharmacol Toxicol 41:569-591, 2001.
62. Avis NE, Brambilla D, McKinlay SM, et al: A longitudinal analysis of the association between menopause and depression. Results from the Massachusetts Women's Health Study. Ann Epidemiol 4:214-220, 1994.
63. Schmidt PJ, Nieman L, Danaceau MA, et al: Estrogen replacement in perimenopause-related depression: A preliminary report. Am J Obstet Gynecol 183:414-420, 2000.
64. de Novaes Soares C, Almeida OP, Joffe H, et al: Efficacy of estradiol for the treatment of depressive disorders in perimenopausal women: A double-blind, randomized, placebo-controlled trial. Arch Gen Psychiatry 58:529-534, 2001.
65. Bines J, Oleske DM, Cobleigh MA: Ovarian function in premenopausal women treated with adjuvant chemotherapy for breast cancer. J Clin Oncol 14:1718-1729, 1996.
66. Ganz PA, Rowland JH, Meyerowitz BE, et al: Impact of different adjuvant therapy strategies on quality of life in breast cancer survivors. Recent Results Cancer Res 152:396-411, 1998.
67. Duffy LS, Greenberg DB, Younger J, et al: Iatrogenic acute estrogen deficiency and psychiatric syndromes in breast cancer patients. Psychosomatics 40:304-308, 1999.
68. Fallowfield L, Fleissig A, Edwards R, et al: Tamoxifen for the prevention of breast cancer: Psychosocial impact on women participating in two randomized controlled trials. J Clin Oncol 19:1885-1892, 2001.
69. Day R, Ganz PA, Costantino JP, et al: Health-related quality of life and tamoxifen in breast cancer prevention: A report from the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Clin Oncol 17:2659-2669, 1999.
70. Cathcart CK, Jones SE, Pumroy CS, et al: Clinical recognition and management of depression in node negative breast cancer patients treated with tamoxifen. Breast Cancer Res Treat 27:277-281, 1993.
71. Dhodapkar M, Ingle J, Cha S, et al: Impact of age on prognosis and toxicity in elderly women with metastatic breast cancer (MBC) treated with tamoxifen (TAM): An analysis of patients entered on four prospective clinical trials (abstract). Proc Am Soc Clin Oncol 14:A106, 1995.
72. Musselman DL, DiBattista C, Nathan KI, et al: Biology of mood disorders, in Schatzberg AF, Nemeroff CB (eds): American Psychiatric Press Textbook of Psychopharmacology, 2nd ed. Washington, DC, APA Press, 1998.
73. Ribiero SCM, Tandon R, Grunhaus L, et al: The DST as a predictor of outcome in depression. A meta-analysis. Am J Psychiatry 150:1618-1629, 1993.
74. Musselman DL, Miller AH, Porter MR, et al: Higher than normal plasma interleukin-6 concentrations in cancer patients with depression. Am J Psychiatry 158:1252-1257, 2001.
75. Swanson LW, Sawchenko PE, Rivier J, et al: Organization of ovine corticotropin-releasing factor immunoreactive cells and fibers in the rat brain: An immunohistochemical study. Neuroendocrinology 36:165-186, 1983.
76. Vale W, Spiess J, Rivier C, et al: Characterization of a 41 residue ovine hypothalamic peptide that stimulates secretion of corticotropin of beta-endorphin. Science 213:1394-1397, 1981.
77. Sephton SE, Sapolsky RM, Kraemer HC, et al: Diurnal cortisol rhythm as a predictor of breast cancer survival. J Natl Cancer Inst 92:994-1000, 2000.
78. Blalock JE: A molecular basis for bidirectional communication between the immune and neuroendocrine systems. Physiol Rev 69:1-32, 1989.
79. Gabay C, Kushner I: Acute-phase proteins and other systemic responses to inflammation. N Engl J Med 340:448-454, 1999.
80. Kent S, Bluthe RM, Kelley KW, et al: Sickness behavior as a new target for drug development. Trends Pharmacol Sci 13:24-28, 1992.
81. Raison CL, Gumnick J, Miller AH: Neuroendocrine-immune interactions: Implications for health and behavior, in Pfaff D, Arnold A, Etgen A, et al (eds): Hormones, Brain and Behavior, vol 5. Boston, Academic Press, 2002.
82. Coe CL: Psychosocial factors and immunity in nonhuman primates: A review. Psychosom Med 55:298-308, 1993.
83. Schleifer SJ, Keller SE, Bond RN, et al: Major depressive disorder and immunity. Role of age, sex, severity, and hospitalization. Arch Gen Psychiatry 46:81-87, 1989.
84. O'Leary A: Stress, emotion, and human immune function. Psychol Bull 108:363-382, 1990.
85. McGee R, Williams S, Elwood M: Depression and the development of cancer: A meta-analysis. Soc Sci Med 38:187-192, 1994.
86. Whooley MA, Browner WS: Association between depressive symptoms and mortality in older women. Study of Osteoporotic Fractures Research Group. Arch Int Med 158:2129-2135, 1998.
87. Friedman GD: Psychiatrically-diagnosed depression and subsequent cancer. Cancer Epidemiol Biomarkers Prev 3:11-13, 1994.
88. Penninx BW, Guralnik JM, Pahor M, et al: Chronically depressed mood and cancer risk in older persons. J Natl Cancer Inst 90:1888-1893, 1998.
89. Gallo JJ, Armenian HK, Ford DE, et al: Major depression and cancer: The 13-year follow-up of the Baltimore epidemiologic catchment area sample (United States). Cancer Causes Control 11:751-758, 2000.
90. Everson SA, Goldberg DE, Kaplan GA, et al: Hopelessness and risk of mortality and incidence of myocardial infarction and cancer. Psychosom Med 58:113-121, 1996.
91. Linkens RW, Comstick GW: Depressed mood and the development of cancer. Am J Epidemiol 132:962-972, 1990.
92. Knekt P, Raitasalo R, Heliovaara M, et al: Elevated lung cancer risk among persons with depressed mood. Am J Epidemiol 144:1096-1103, 1996.
93. Butow PN, Hiller JE, Price MA, et al: Epidemiological evidence for a relationship between life events, coping style, and personality factors in the development of breast cancer. J Psychosom Res 49:169-181, 2000.
94. Barraclough J, Pinder P, Cruddas M, et al: Life events and breast cancer prognosis. BMJ 304:1078-1081, 1992.
95. Graham J, Ramirez AJ, Love S, et al: Stressful life experiences and risk of relapse of breast cancer: Observational cohort study. BMJ 324:1420-1423, 2002.
96. Stein M, Miller AH, Trestman RL: Depression, the immune system, and health and illness. Findings in search of meaning. Arch Gen Psychiatry 48:171-177, 1991.
97. Levy S, Herberman R, Lippman M, et al: Correlation of stress factors with sustained depression of natural killer cell activity and predicted prognosis in patients with breast cancer. J Clin Oncol 5:348-353, 1987.
98. Levy SM, Herberman RB, Lee J, et al: Estrogen receptor concentration and social factors as predictors of natural killer cell activity in early-stage breast cancer patients. Confirmation of a model. Nat Immun Cell Growth Regul 9:313-324, 1990.
99. Hyman SE, Arana GW, Rosenbaum JF: Handbook of Psychiatric Drug Therapy. Boston, Little Brown & Co, 1995.
100. Golden RN, Dawkins K, Nicholas L: Trazodone and nefazodone, in Schatzberg AF, Nemeroff CB (eds): The American Psychiatric Publishing Textbook of Psychopharmacology. Washington, DC, American Psychiatric Publishing, 2004.
101. Hudziak JJ, Rettew DC: Bupropion, in Schatzberg AF, Nemeroff CB (eds): The American Psychiatric Publishing Textbook of Psychopharmacology, 3rd ed. Washington, DC, American Psychiatric Publishing, 2004.
102. Nemeroff CB, DeVane CL, Pollock BG: Newer antidepressants and the cytochrome P450 system. Am J Psychiatry 153:311-320, 1996.
103. Burstein HJ, Winer EP: Primary care for survivors of breast cancer. N Engl J Med 343:1086-1094, 2000.
104. Costa E, Mogos I, Toma T: Efficacy and safety of mianserin in the treatment of depression of women with cancer. Acta Psychiatr Scand 72:85-92, 1985.
105. Razavi D, Allilaire JF, Smith M, et al: The effect of fluoxetine on anxiety and depression symptoms in cancer patients. Acta Psychiatr Scand 94:205-210, 1996.
106. Van Heeringen K, Zivkov M: Pharmacological treatment of depression in cancer patients. A placebo-controlled study of mianserin. Br J Psychiatry 169:440-443, 1996.
107. Holland JC, Romano SJ, Heiligenstein JH, et al: A controlled trial of fluoxetine and desipramine in depressed women with advanced cancer. Psychooncology 300:291-300, 1998.
108. Hamilton M: The assessment of anxiety states by rating. Br J Med Psychol 32:59-55, 1959.
109. Loprinzi CL, Pisansky TM, Fonseca R, et al: Pilot evaluation of venlafaxine hydrochloride for the therapy of hot flashes in cancer survivors. J Clin Oncol 16:2377-2381, 1998.
110. Stearns V, Isaacs C, Rowland JH, et al: A pilot trial assessing the efficacy of paroxetine hydrochloride (Paxil) in controlling hot flashes in breast cancer survivors. Ann Oncol 11:1-6, 2000.
111. Fawzy FI, Fawzy NW, Arndt LA, et al: Critical review of psychosocial interventions in cancer care. Arch Gen Psychiatry 52:100-113, 1995.
112. Massie MJ: Depression, in Holland JC, Rowland JH (eds): Handbook of Psychooncology: Psychological Care of the Patient with Cancer. New York, Oxford University Press, 1990.
113. Spiegel D, Bloom JR, Kraemer HC, et al: Effect of psychosocial treatment on survival of patients with metastatic breast cancer. Lancet 2:888-891, 1989.
114. Fukui S, Kugaya A, Okamura H, et al: A psychosocial group intervention for Japanese women with primary breast carcinoma. Cancer 89:1026-1036, 2000.
115. Antoni MH, Lehman JM, Kilborn KM, et al: Cognitive-behavioral stress management intervention decreases the prevalence of depression and enhances benefit finding among women under treatment for early-stage breast cancer. Health Psychol 20:20-32, 2001.
116. Classen C, Butler L, Koopman C, et al: Supportive-expressive group therapy and distress in patients with metastatic breast cancer: A randomized clinical intervention trial. Arch Gen Psychiatry 58:494-501, 2001.
117. Montazeri A, Jarvandi S, Haghighat S, et al: Anxiety and depression in breast cancer patients before and after participation in a cancer support group. Patient Educ Couns 45:195-198, 2001.
118. Fox BH: A hypothesis about Spiegel et al's 1989 paper on psychosocial intervention and breast cancer survival. Psychooncology 7:361-370, 1998.
119. Cunningham AJ, Admonds CV, Jenkins GP, et al: A randomized controlled trial of the effects of group psychological therapy on survival in women with metastatic breast cancer. Psychooncology 7:508-517, 1998.
120. Edelman S, Lemon J, Bell DR, et al: Effects of group CBT on the survival time of patients with metastatic breast cancer. Psychooncology 8:474-481, 1999.
121. Goodwin P, Leszcz M, Ennis M, et al: The effect of group psychosocial support on survival in metastatic breast cancer. N Engl J Med 345:1719-1726, 2001.
122. Spiegel D: Effects of psychotherapy on cancer survival. Nat Rev Cancer 2:383-389, 2002.
123. Simpson JS, Carlson LE, Trew ME: Effect of group therapy for breast cancer on healthcare utilization. Cancer Prac 9:19-26, 2001.
124. Musselman DL, Lawson DH, Gumnick JF, et al: Paroxetine for the prevention of the depression and neurotoxicity induced by high dose interferon-alpha therapy. N Engl J Med 344:961-966, 2001.
125. Pezzella G, Moslinger-Gehmayr R, Contu A: Treatment of depression in patients with breast cancer: A comparison between paroxetine and amitryptyline. Br Can Res and Treat 70:1-10, 2001.